Clinical trials · Massachusetts
Lung cancer clinical trials in Massachusetts
We’re tracking 175 recruiting lung cancer studies with a site in Massachusetts — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT07315113RecruitingPhase 1
Study of NXP900 plus osimertinib for EGFR lung cancer
This trial tests a new study drug called NXP900 combined with the targeted therapy osimertinib for people with advanced EGFR-mutated lung cancer who have already been treated with osimertinib. The goal is to see if the combination can help shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06538038Recruiting
Osimertinib plus chemo vs. osimertinib alone for EGFR-mutated NSCLC
This study compares two standard treatments for advanced lung cancer with an EGFR mutation: osimertinib alone versus osimertinib plus chemotherapy. It aims to see which approach works better and is not a trial of a new drug, so you can receive usual care while contributing data.
Lowell, MassachusettsAges 18 years+ - NCT06538636Recruiting
Improving lung cancer screening for Veterans
This study is testing a new way to find Veterans who might benefit from yearly lung cancer screening. It uses a computer model to estimate your personal benefit, even if you don't fit the usual screening guidelines.
Boston, MassachusettsAges 50–80 - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06910956Recruiting
Finding high-risk patients for lung cancer screening using chest X-rays
This trial uses artificial intelligence to analyze chest X-rays and identify people who may be at high risk for lung cancer and could benefit from a CT screening scan. It's designed for current or former smokers aged 50 to 77 who have had a recent chest X-ray and are not already being checked for lung cancer.
Boston, MassachusettsAges 50–77 - NCT07005128RecruitingPhase 3
New Drug Combo for First-Line Extensive Small Cell Lung Cancer
This trial tests adding a new immunotherapy drug (tarlatamab) to the standard first-line chemo-immunotherapy for extensive-stage small cell lung cancer. It aims to see if the combination works better than the usual treatment alone.
Boston, MassachusettsAges 18–99 - NCT07059884Recruiting
Exercise program to help people with cancer stay active
This trial tests a distance-based exercise program designed to help people on chemotherapy maintain their physical function and prevent disability. It is for patients with certain cancers who are working full-time and can participate in moderate physical activity.
Boston, MassachusettsAges 18 years+ - NCT02012699Recruiting
Cancer registry for people with or at risk of cancer
This trial collects health information and samples (a “cancer repository”) to help researchers study cancer and cancer risk. You may be able to join if you’ve had cancer before or if you’re at higher risk or have concerning findings.
Holyoke, MassachusettsAges 19–110 - NCT02468024RecruitingPhase 3
Surgery or focused radiation for early lung cancer
This study compares two treatments—removing only part of the lung (sublobar resection) versus a focused radiation approach (stereotactic ablative radiotherapy)—for early-stage non-small cell lung cancer. It aims to see which option works better with fewer problems for the right patients.
Boston, MassachusettsAges 18 years+ - NCT06162221RecruitingPhase 1/Phase 2
Study of RAS inhibitors for advanced RAS-mutated lung cancer
This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.
Boston, MassachusettsAges 18 years+ - NCT00471978Recruiting
Analyzing DNA from blood and lung tumor tissue
This study looks at DNA from blood samples and lung tumor tissue in people newly diagnosed with primary lung cancer. The goal is to learn more about the cancer’s biology and possibly guide better future care.
Boston, MassachusettsAges 18–120 - NCT07517692Enrolling by invitation
Improving shared decision-making for lung cancer screening
This study tests a new way to help patients and doctors discuss lung cancer screening together using text messages and shared decision-making tools. It may help you understand screening options better and make choices that fit your values.
Worcester, MassachusettsAges 50–77 - NCT06122077Recruiting
Blood test for early lung cancer detection in smokers
This trial tests a blood test that looks for multiple signals to find lung cancer early. If you are a smoker or former smoker over 50, this test might help detect cancer before you have symptoms.
Hyannis, MassachusettsAges 50 years+ - NCT06252129Recruiting
Improving Lymph Node Removal During Lung Cancer Surgery
This trial studies a better way to remove and examine lymph nodes from lung cancer surgery specimens. It aims to improve how doctors check for cancer spread, which may help guide your treatment after surgery.
Boston, MassachusettsAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Boston, MassachusettsAges 18 years+ - NCT07127874RecruitingPhase 1
Study of PHN-012 for advanced solid tumors
This trial tests a new drug called PHN-012 for people with advanced colorectal, non-small cell lung, or pancreatic cancer who have already tried at least one standard treatment. The goal is to see if the drug can help shrink or slow tumor growth.
Boston, MassachusettsAges 18 years+ - NCT05898594Recruiting
Lung cancer screening for high-risk Black adults
This study is designed to help Black adults at higher risk get lung cancer screening. It checks whether a screening approach can catch lung problems early and connect people to the right next steps.
Boston, MassachusettsAges 50–80 - NCT07155174RecruitingPhase 2
Testing new drug combo for first-line extensive small cell lung cancer
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
Boston, MassachusettsAges 18 years+ - NCT07361497RecruitingPhase 3
New Drug vs Standard Drug After Chemoradiation for Stage 3 Lung Cancer
This study tests a new drug, pumitamig, against an older drug, durvalumab, for people with stage 3 non-small cell lung cancer that cannot be removed by surgery and has not progressed after chemotherapy and radiation. The goal is to see which drug works better to keep the cancer from growing.
Boston, MassachusettsAges 18 years+ - NCT06203210RecruitingPhase 3
Study of a new drug for relapsed small cell lung cancer
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
Boston, MassachusettsAges 18 years+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Boston, MassachusettsAges 18 years+ - NCT06931626RecruitingPhase 1
Study of NMS-03305293 for relapsed small cell lung cancer
This trial tests a new drug, NMS-03305293, in adults with small cell lung cancer that has come back after earlier treatments. The goal is to see if it can help shrink or slow the cancer.
Boston, MassachusettsAges 18 years+ - NCT05797168RecruitingPhase 1/Phase 2
Early study drug for advanced solid tumors, alone or with another drug
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
Boston, MassachusettsAges 18–130 - NCT06095505RecruitingPhase 2
Alisertib for extensive stage small cell lung cancer
This trial tests a new drug called alisertib for people with small cell lung cancer that has spread. It is for those who have already tried standard treatments (chemotherapy and immunotherapy) and need another option.
Boston, MassachusettsAges 18 years+
Lung cancer trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting lung cancer studies listed above.
- Massachusetts General Hospital · 8 studies
- Dana-Farber Cancer Institute · 7 studies
- Beth Israel Deaconess Medical Center
- Boston Medical Center
- Brigham and Women's Hospital
- Cape Cod Hospital
- Harvard TH Chan School of Public Health
- Holyoke Medical Center Inc
What taking part in a lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Lung cancer trials in other states
Common questions
- Are there lung cancer clinical trials in Massachusetts?
- Yes. We're currently tracking 175 recruiting lung cancer studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung cancer study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung cancer studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.